Drug Insights \ January 2016

Drug Pipeline Update

New Drug Information

- **Humulin R U-500 KwikPen (insulin human injection)**: The Food and Drug Administration (FDA) approved Eli Lilly’s pre-filled insulin device for patients with type 1 and type 2 diabetes who require more than 200 units of insulin per day. Previously, U-500 insulin has only been available in vials.

- **Adzenys XR-ODT™ (amphetamine extended-release orally disintegrating tablet)**: Neos Therapeutics received FDA approval for their ADHD treatment in people ages 6 and older. Adzenys is similar to Adderall® XR.

- **Zurampic™ (lesinurad)**: The FDA approved AstraZeneca’s Zurampic for the treatment of gout. Zurampic is to be used in combination with a xanthine oxidase inhibitor (i.e. allopurinol, Uloric®) in patients who do not reach target serum uric acid levels on a xanthine oxidase inhibitor alone.

New Generics

- **Ortho Tri-Cyclen Lo® (norgestimate/ethinyl estradiol)**: Generic versions of Jannsen’s oral contraceptive Ortho Tri-Cyclen Lo are now available. According to IMS Health, Ortho Tri-Cyclen Lo had $488.4 million in annual U.S. sales.

- **Gleevec® (imatinib)**: Sun Pharma has launched the first generic of Novartis’ oral oncology drug, Gleevec, and will have 180 days of marketing exclusivity. According to IMS Health, Gleevec had approximately $2.2 billion in annual U.S. sales.

While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status. Each trademarked drug name is the property of its respective owner.